A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells

Glycoconjugate Journal

Volumn 30, Issue 7, 2013, Pages 687-699

  Casadesús, Ana Victoria ^a   Fernández Marrero, Yuniel ^a,b   Clavell, Marilyn ^a   Gómez, José Alberto ^a   Hernández, Tays ^a   Moreno, Ernesto ^a   López Requena, Alejandro ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

cmah; Cytotoxic antibody; GM3 ganglioside; Neu5Gc; Tumorigenicity

Indexed keywords

CYTIDINE MONOPHOSPHO N ACETYL NEURAMINIC ACID HYDROLASE; GANGLIOSIDE GM3; HYDROLASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14F7; MONOCLONAL ANTIBODY 7C1; N ACETYL SIALIC ACID; N GLYCOLYL SIALIC ACID; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CMAH GENE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; G(M3) GANGLIOSIDE; HEK293 CELLS; HUMANS; LEUKEMIA, LYMPHOID; MICE; MICE, INBRED DBA; MIXED FUNCTION OXYGENASES; N-ACETYLNEURAMINIC ACID;

EID: 84884584862     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-013-9473-y     Document Type: Article

References (89)

1. Hakomori, S.: Structure, organization, and function of glycosphingolipids in membrane. Curr. Opin. Hematol. 10(1), 16-24 (2003)
2. Lopez, P.H., Schnaar, R.L.: Gangliosides in cell recognition and membrane protein regulation. Curr. Opin. Struct. Biol. 19(5), 549-557 (2009). doi: 10.1016/j.sbi.2009.06.001
3. Sonnino, S., Mauri, L., Chigorno, V., Prinetti, A.: Gangliosides as components of lipid membrane domains. Glycobiology 17(1), 1R-13R (2007). doi: 10.1093/glycob/cwl052
4. Sonnino, S., Prinetti, A.: Lipids and membrane lateral organization. Front. Physiol. 1, 153 (2010). doi: 10.3389/fphys.2010.00153
5. Cantu, L., Del Favero, E., Sonnino, S., Prinetti, A.: Gangliosides and the multiscale modulation of membrane structure. Chem. Phys. Lipids 164(8), 796-810 (2011). doi: 10.1016/j.chemphyslip.2011.09.005
6. Hakomori, S.: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56(23), 5309-5318 (1996)
7. Prinetti, A., Prioni, S., Loberto, N., Aureli, M., Nocco, V., Illuzzi, G., Mauri, L., Valsecchi, M., Chigorno, V., Sonnino, S.: Aberrant glycosphingolipid expression and membrane organization in tumor cells: consequences on tumor-host interactions. Adv. Exp. Med. Biol. 705, 643-667 (2011). doi: 10.1007/978-1-4419-7877-6-34
8. Durrant, L.G., Noble, P., Spendlove, I.: Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin. Exp. Immunol. 167(2), 206-215 (2012). doi: 10.1111/j.1365-2249.2011.04516.x
9. Rabu, C., McIntosh, R., Jurasova, Z., Durrant, L.: Glycans as targets for therapeutic antitumor antibodies. Future Oncol. 8(8), 943-960 (2012). doi: 10.2217/fon.12.88
10. Higashi, H., Hirabayashi, Y., Fukui, Y., Naiki, M., Matsumoto, M., Ueda, S., Kato, S.: Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. Cancer Res. 45(8), 3796-3802 (1985)
11. Marquina, G., Waki, H., Fernandez, L.E., Kon, K., Carr, A., Valiente, O., Perez, R., Ando, S.: Gangliosides expressed in human breast cancer. Cancer Res. 56(22), 5165-5171 (1996)
12. Varki, A.: Multiple changes in sialic acid biology during human evolution. Glycoconj. J. 26(3), 231-245 (2009). doi: 10.1007/s10719-008-9183-z
13. Irie, A., Koyama, S., Kozutsumi, Y., Kawasaki, T., Suzuki, A.: The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 273(25), 15866-15871 (1998)
14. Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., Muchmore, E.: Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U. S. A. 100(21), 12045-12050 (2003). doi: 10.1073/pnas.2131556100
15. Bardor, M., Nguyen, D.H., Diaz, S., Varki, A.: Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280(6), 4228-4237 (2005). doi: 10.1074/jbc.M412040200
16. Banda, K., Gregg, C.J., Chow, R., Varki, N.M., Varki, A.: Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid. J. Biol. Chem. 287(34), 28852-28864 (2012). doi: 10.1074/jbc.M112.364182
17. Hedlund, M., Tangvoranuntakul, P., Takematsu, H., Long, J.M., Housley, G.D., Kozutsumi, Y., Suzuki, A., Wynshaw-Boris, A., Ryan, A.F., Gallo, R.L., Varki, N., Varki, A.: N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol. Cell. Biol. 27(12), 4340-4346 (2007). doi: 10.1128/MCB.00379-07
18. Yin, J., Hashimoto, A., Izawa, M., Miyazaki, K., Chen, G.Y., Takematsu, H., Kozutsumi, Y., Suzuki, A., Furuhata, K., Cheng, F.L., Lin, C.H., Sato, C., Kitajima, K., Kannagi, R.: Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 66(6), 2937-2945 (2006). doi: 10.1158/0008-5472.CAN-05-2615
19. Yin, J., Miyazaki, K., Shaner, R.L., Merrill Jr., A.H., Kannagi, R.: Altered sphingolipid metabolism induced by tumor hypoxia - new vistas in glycolipid tumor markers. FEBS Lett. 584(9), 1872-1878 (2010). doi: 10.1016/j.febslet.2009.11.019
20. Carr, A., Mullet, A., Mazorra, Z., Vazquez, A.M., Alfonso, M., Mesa, C., Rengifo, E., Perez, R., Fernandez, L.E.: A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19(3), 241-247 (2000). doi: 10.1089/02724570050109639
21. Oliva, J.P., Valdes, Z., Casaco, A., Pimentel, G., Gonzalez, J., Alvarez, I., Osorio, M., Velazco, M., Figueroa, M., Ortiz, R., Escobar, X., Orozco, M., Cruz, J., Franco, S., Diaz, M., Roque, L., Carr, A., Vazquez, A.M., Mateos, C., Rubio, M.C., Perez, R., Fernandez, L.E.: Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99 m)Tc. Breast Cancer Res. Treat. 96(2), 115-121 (2006). doi: 10.1007/s10549-005-9064-0
22. Fernandez-Marrero, Y., Roque-Navarro, L., Hernandez, T., Dorvignit, D., Molina-Perez, M., Gonzalez, A., Sosa, K., Lopez-Requena, A., Perez, R., Mateo de Acosta, C.: A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology (2011). doi: 10.1016/j.imbio.2011.07.004
23. Osorio, M., Gracia, E., Rodriguez, E., Saurez, G., Arango Mdel, C., Noris, E., Torriella, A., Joan, A., Gomez, E., Anasagasti, L., Gonzalez, J.L., Melgares Mde, L., Torres, I., Gonzalez, J., Alonso, D., Rengifo, E., Carr, A., Perez, R., Fernandez, L.E.: Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol. Ther. 7(4), 488-495 (2008)
24. Blanco, R., Rengifo, E., Rengifo, C.E., Cedeno, M., Frometa, M., Carr, A.: Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-glycolyl GM3 ganglioside in some benign and malignant skin neoplasms. ISRN Dermatol. 2011, 848909 (2011). doi: 10.5402/2011/848909
25. Zhong, Y., Wu, Y., Li, C., Tang, J., Wang, X., Ren, G., Carr, A., Perez, R., Guo, W.: N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese. Oral Dis. 18(8), 741-747 (2012). doi: 10.1111/j.1601-0825. 2012.01939.x
26. van Cruijsen, H., Ruiz, M.G., van der Valk, P., de Gruijl, T.D., Giaccone, G.: Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9, 180 (2009). doi: 10.1186/1471-2407-9- 180
27. Blanco, R., Rengifo, C.E., Cedeno, M., Frometa, M., Rengifo, E., Carr, A.: Immunoreactivity of the 14F7 mab (raised against N-glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Patholog. Res. Int. 2012, 235418 (2012). doi: 10.1155/2012/235418
28. Hayashi, N., Chiba, H., Kuronuma, K., Go, S., Hasegawa, Y., Takahashi, M., Gasa, S., Watanabe, A., Hasegawa, T., Kuroki, Y., Inokuchi, J., Takahashi, H.: Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci. 104(1), 43-47 (2013). doi: 10.1111/cas.12027
29. Scursoni, A.M., Galluzzo, L., Camarero, S., Pozzo, N., Gabri, M.R., de Acosta, C.M., Vazquez, A.M., Alonso, D.F., de Davila, M.T.: Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr. Dev. Pathol. 13(1), 18-23 (2010). doi: 10.2350/08-10-0544.1
30. Scursoni, A.M., Galluzzo, L., Camarero, S., Lopez, J., Lubieniecki, F., Sampor, C., Segatori, V.I., Gabri, M.R., Alonso, D.F., Chantada, G., de Davila, M.T.: Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin. Dev. Immunol. 2011, 245181 (2011). doi: 10.1155/2011/245181
31. Sampor, C., Guthmann, M.D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., Camarero, S., Lopez, J., de Davila, M.T., Fainboim, L., Chantada, G.L.: Immune response to racotumomab in a child with relapsed neuroblastoma. Front. Oncol. 2, 195 (2012). doi: 10.3389/fonc.2012.00195
32. Blanco, R., Quintana, Y., Blanco, D., Cedeño, M., Rengifo, C.E., Frómeta, M., Ríos, M., Rengifo, E., Carr, A.: Tissue reactivity of the 14F7 mab raised against N-Glycolyl GM3 ganglioside in tumors of neuroectodermal, mesodermal, and epithelial origin. J. Biomarkers 2013, 602417 (2013). doi: 10.1155/2013/602417
33. Blanco, R., Rengifo, E., Cedeno, M., Rengifo, C.E., Alonso, D.F., Carr, A.: Immunoreactivity of the 14F7 mab raised against N-glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system. ISRN Gastroenterol. 2011, 645641 (2011). doi: 10.5402/2011/645641
34. Blanco, R., Cedeño, M., Escobar, X., Blanco, D., Rengifo, C.E., Frómeta, M., Alvarez, R.I., Rengifo, E., Carr, A.: Immunorecognition of the 14F7 mab raised against N-glycolyl GM3 ganglioside in some normal and malignant tissues from genitourinary system. ISRN Pathology 2011, 953803 (2011). doi: 10.5402/2011/953803
35. Fernandez, L.E., Gabri, M.R., Guthmann, M.D., Gomez, R.E., Gold, S., Fainboim, L., Gomez, D.E., Alonso, D.F.: NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin. Dev. Immunol. 2010, 814397 (2010). doi: 10.1155/2010/814397
36. Carr, A., Rodriguez, E., Arango Mdel, C., Camacho, R., Osorio, M., Gabri, M., Carrillo, G., Valdes, Z., Bebelagua, Y., Perez, R., Fernandez, L.E.: Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21(6), 1015-1021 (2003)
37. Mulens, V., de la Torre, A., Marinello, P., Rodriguez, R., Cardoso, J., Diaz, R., O'Farrill, M., Macias, A., Viada, C., Saurez, G., Carr, A., Crombet, T., Mazorra, Z., Perez, R., Fernandez, L.E.: Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 6(9) (2010). doi: 10.4161.hv.6.9.12571
38. Perez, K., Osorio, M., Hernandez, J., Carr, A., Fernandez, L.E.: NGcGM3/VSSP vaccine as treatment for melanoma patients. Hum. Vaccin. Immunother. 9(6) (2013)
39. Vazquez, A.M., Hernandez, A.M., Macias, A., Montero, E., Gomez, D.E., Alonso, D.F., Gabri, M.R., Gomez, R.E.: Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front. Oncol. 2, 150 (2012). doi: 10.3389/fonc.2012.00150
40. Vazquez, A.M., Alfonso, M., Lanne, B., Karlsson, K.A., Carr, A., Barroso, O., Fernandez, L.E., Rengifo, E., Lanio, M.E., Alvarez, C., et al.: Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14(6), 551-556 (1995)
41. Carr, A., Mesa, C., del Carmen Arango, M., Vazquez, A.M., Fernandez, L.E.: In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics 21(6), 463-468 (2002). doi: 10.1089/153685902321043990
42. Roque-Navarro, L., Chakrabandhu, K., de Leon, J., Rodriguez, S., Toledo, C., Carr, A., de Acosta, C.M., Hueber, A.O., Perez, R.: Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther. 7(7), 2033-2041 (2008). doi: 10.1158/1535-7163.MCT-08-0222
43. Mateo, C., Lombardero, J., Moreno, E., Morales, A., Bombino, G., Coloma, J., Wims, L., Morrison, S.L., Perez, R.: Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 19(6), 463-471 (2000). doi: 10.1089/027245700750053959
44. Fernandez-Marrero, Y., Lopez-Requena, A.: Lonely killers: Effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs 3(6), 528-534 (2011). doi: 10.4161/mabs.3.6.17770
45. Fernandez-Marrero, Y., Hernandez, T., Roque-Navarro, L., Talavera, A., Moreno, E., Grinan, T., Vazquez, A.M., de Acosta, C.M., Perez, R., Lopez-Requena, A.: Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Mol. Immunol. 48(8), 1059-1067 (2011). doi: 10.1016/j.molimm.2011.01.008
46. Rojas, G., Pupo, A., Gomez, S., Krengel, U., Moreno, E.: Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. ACS Chem. Biol. 8(2), 376-386 (2013). doi: 10.1021/cb3003754
47. Vazquez, A.M., Tormo, B., Velandia, A., Giscombe, R., Ansotegui, I., Jeddi-Tehrani, M., Perez, R., Mellstedt, H., Biberfeld, P.: Characterization of the colorectal antigen IOR-C2. Hybridoma 11(2), 245-256 (1992)
48. Roque-Navarro, L., Mateo, C., Lombardero, J., Mustelier, G., Fernandez, A., Sosa, K., Morrison, S.L., Perez, R.: Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 22(4), 245-257 (2003). doi: 10.1089/153685903322328974
49. de Leon, J., Fernandez, A., Mesa, C., Clavel, M., Fernandez, L.E.: Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol. Immunother. 55(4), 443-450 (2006). doi: 10.1007/s00262-005-0041-6
50. Svennerholm, L.: Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim. Biophys. Acta 24(3), 604-611 (1957)
51. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193(1), 265-275 (1951)
52. Lopez-Requena, A., Mateo de Acosta, C., Perez, A., Valle, A., Lombardero, J., Sosa, K., Perez, R., Vazquez, A.M.: Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics 22(4), 235-243 (2003)
53. Meisen, I., Peter-Katalinic, J., Muthing, J.: Direct analysis of silica gel extracts from immunostained glycosphingolipids by nanoelectrospray ionization quadrupole time-of-flight mass spectrometry. Anal. Chem. 76(8), 2248-2255 (2004). doi: 10.1021/ac035511t
54. Lemaire, R., Tabet, J.C., Ducoroy, P., Hendra, J.B., Salzet, M., Fournier, I.: Solid ionic matrixes for direct tissue analysis and MALDI imaging. Anal. Chem. 78(3), 809-819 (2006). doi: 10.1021/ac0514669
55. Strohalm, M., Kavan, D., Novak, P., Volny, M., Havlicek, V.: mMass 3: a cross-platform software environment for precise analysis of mass spectrometric data. Anal. Chem. 82(11), 4648-4651 (2010). doi: 10.1021/ac100818g
56. Cycon, K.A., Clements, J.L., Holtz, R., Fuji, H., Murphy, S.P.: The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology 128(1 Suppl), e641-e651 (2009). doi: 10.1111/j.1365-2567.2009.03052.x
57. Portoukalian, J., Zwingelstein, G., Dore, J.F.: Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur. J. Biochem. 94(1), 19-23 (1979)
58. Tsuchida, T., Saxton, R.E., Morton, D.L., Irie, R.F.: Gangliosides of human melanoma. J. Natl. Cancer. Inst. 78(1), 45-54 (1987)
59. Ravindranath, M.H., Muthugounder, S., Presser, N., Selvan, S.R., Santin, A.D., Bellone, S., Saravanan, T.S., Morton, D.L.: Immunogenic gangliosides in human ovarian carcinoma. Biochem. Biophys. Res. Commun. 353(2), 251-258 (2007). doi: 10.1016/j.bbrc.2006.12.001
60. Dohi, T., Nores, G., Hakomori, S.: An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res. 48(20), 5680-5685 (1988)
61. Hoon, D.S., Wang, Y., Sze, L., Kanda, H., Watanabe, T., Morrison, S.L., Morton, D.L., Irie, R.F.: Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res. 53(21), 5244-5250 (1993)
62. Takahashi, T., Johnson, T.D., Nishinaka, Y., Morton, D.L., Irie, R.F.: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 112(2), 205-209 (1999). doi: 10.1046/j.1523-1747.1999.00493.x
63. Irie, R.F., Ollila, D.W., O'Day, S., Morton, D.L.: Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol. Immunother. 53(2), 110-117 (2004). doi: 10.1007/s00262-003-0436-1
64. Hakomori, S.I.: Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett. 584(9), 1901-1906 (2010). doi: 10.1016/j.febslet.2009.10.065
65. Handa, K., Hakomori, S.I.: Carbohydrate to carbohydrate interaction in development process and cancer progression. Glycoconj. J. (2012). doi: 10.1007/s10719-012-9380-7
66. Watanabe, R., Ohyama, C., Aoki, H., Takahashi, T., Satoh, M., Saito, S., Hoshi, S., Ishii, A., Saito, M., Arai, Y.: Ganglioside G(M3) overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 62(13), 3850-3854 (2002)
67. Prinetti, A., Aureli, M., Illuzzi, G., Prioni, S., Nocco, V., Scandroglio, F., Gagliano, N., Tredici, G., Rodriguez-Menendez, V., Chigorno, V., Sonnino, S.: GM3 synthase overexpression results in reduced cell motility and in caveolin-1 upregulation in human ovarian carcinoma cells. Glycobiology 20(1), 62-77 (2010). doi: 10.1093/glycob/cwp143
68. Prinetti, A., Cao, T., Illuzzi, G., Prioni, S., Aureli, M., Gagliano, N., Tredici, G., Rodriguez-Menendez, V., Chigorno, V., Sonnino, S.: A glycosphingolipid/caveolin-1 signaling complex inhibits motility of human ovarian carcinoma cells. J. Biol. Chem. 286(47), 40900-40910 (2011). doi: 10.1074/jbc.M111.286146
69. Nojiri, H., Yamana, H., Shirouzu, G., Suzuki, T., Isono, H.: Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy. Cancer Detect. Prev. 26(2), 114-120 (2002)
70. Tringali, C., Lupo, B., Cirillo, F., Papini, N., Anastasia, L., Lamorte, G., Colombi, P., Bresciani, R., Monti, E., Tettamanti, G., Venerando, B.: Silencing of membrane-associated sialidase Neu3 diminishes apoptosis resistance and triggers megakaryocytic differentiation of chronic myeloid leukemic cells K562 through the increase of ganglioside GM3. Cell Death Differ. 16(1), 164-174 (2009). doi: 10.1038/cdd.2008.141
71. Prinetti, A., Loberto, N., Chigorno, V., Sonnino, S.: Glycosphingolipid behaviour in complex membranes. Biochim. Biophys. Acta 1788(1), 184-193 (2009). doi: 10.1016/j.bbamem.2008.09.001
72. Gabri, M.R., Otero, L.L., Gomez, D.E., Alonso, D.F.: Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J. Exp. Clin. Cancer Res. 28, 146 (2009). doi: 10.1186/1756-9966-28-146
73. Segatori, V.I., Vazquez, A.M., Gomez, D.E., Gabri, M.R., Alonso, D.F.: Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front. Oncol. 2, 160 (2012). doi: 10.3389/fonc.2012.00160
74. Segatori, V.I., Otero, L.L., Fernandez, L.E., Gomez, D.E., Alonso, D.F., Gabri, M.R.: Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In Vivo 26(4), 609-617 (2012)
75. Labrada, M., Clavell, M., Bebelagua, Y., Leon, J., Alonso, D.F., Gabri, M.R., Veloso, R.C., Verez, V., Fernandez, L.E.: Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert. Opin. Biol. Ther. 10(2), 153-162 (2010). doi: 10.1517/14712590903443084
76. Miura, Y., Kainuma, M., Jiang, H., Velasco, H., Vogt, P.K., Hakomori, S.: Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc. Natl. Acad. Sci. U. S. A. 101(46), 16204-16209 (2004). doi: 10.1073/pnas.0407297101
77. Liu, J.W., Sun, P., Yan, Q., Paller, A.S., Gerami, P., Ho, N., Vashi, N., Le Poole, I.C., Wang, X.Q.: De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res. 69(22), 8662-8669 (2009). doi: 10.1158/0008-5472.CAN-09-1099
78. Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011). doi: 10.1016/j.cell.2011.02.013
79. Birkle, S., Zeng, G., Gao, L., Yu, R.K., Aubry, J.: Role of tumor-associated gangliosides in cancer progression. Biochimie 85(3-4), 455-463 (2003)
80. Potapenko, M., Shurin, G.V., de Leon, J.: Gangliosides as immunomodulators. Adv. Exp. Med. Biol. 601, 195-203 (2007)
81. de Leon, J., Fernandez, A., Clavell, M., Labrada, M., Bebelagua, Y., Mesa, C., Fernandez, L.E.: Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4 + CD25- effector and naturally occurring CD4 + CD25+ regulatory T cells function. Int. Immunol. 20(4), 591-600 (2008). doi: 10.1093/intimm/dxn018
82. Sorice, M., Pavan, A., Misasi, R., Sansolini, T., Garofalo, T., Lenti, L., Pontieri, G.M., Frati, L., Torrisi, M.R.: Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand. J. Immunol. 41(2), 148-156 (1995)
83. Garofalo, T., Sorice, M., Misasi, R., Cinque, B., Giammatteo, M., Pontieri, G.M., Cifone, M.G., Pavan, A.: A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase c delta translocation. J. Biol. Chem. 273(52), 35153-35160 (1998)
84. Shurin, G.V., Shurin, M.R., Bykovskaia, S., Shogan, J., Lotze, M.T., Barksdale Jr., E.M.: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61(1), 363-369 (2001)
85. Peguet-Navarro, J., Sportouch, M., Popa, I., Berthier, O., Schmitt, D., Portoukalian, J.: Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170(7), 3488-3494 (2003)
86. Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., Varki, A.: Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18(10), 818-830 (2008). doi: 10.1093/glycob/cwn072
87. Taylor, R.E., Gregg, C.J., Padler-Karavani, V., Ghaderi, D., Yu, H., Huang, S., Sorensen, R.U., Chen, X., Inostroza, J., Nizet, V., Varki, A.: Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J. Exp. Med. 207(8), 1637-1646 (2010). doi: 10.1084/jem.20100575
88. Hedlund, M., Padler-Karavani, V., Varki, N.M., Varki, A.: Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc. Natl. Acad. Sci. U. S. A. 105(48), 18936-18941 (2008). doi: 10.1073/pnas.0803943105
89. Fuji, H., Iribe, H.: Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Cancer Res. 46(11), 5541-5547 (1986)